Shio-Shin Jean1,2, Wen-Chien Ko3, Min-Chi Lu4, Wen-Sen Lee5, Po-Ren Hsueh6,7,8,9. 1. Department of Pharmacy, College of Pharmacy and Health care, Tajen University, Pingtung, Taiwan. 2. Departments of Emergency and Critical Care Medicine, Min-Sheng General Hospital, Taoyuan, Taiwan. 3. Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. 4. Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung, Taiwan. 5. Division of Infectious Diseases, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University; and Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 6. Departments of Laboratory Medicine and Internal Medicine, China Medical University Hospital, School of Medicine, China Medical University, Taichung, Taiwan. 7. School of Medicine, China Medical University, Taichung, Taiwan. 8. Ph.D Program for Aging, School of Medicine, China Medical University, Taichung, Taiwan. 9. Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Abstract
OBJECTIVES: To determine the in vitro activities of novel and comparator antibiotics against Gram-negative bacteria (GNB) in Taiwan. METHODS: Isolates of Escherichia coli (n = 335), Klebsiella pneumoniae (n = 316; 144 isolates with hyperviscosity characteristics), Pseudomonas aeruginosa (n = 271), Acinetobacter baumannii complex (n = 187), and non-typhoidal Salmonella species (n = 226), Shigella species (n = 13) from miscellaneous culture sources were collected in 2020 in Taiwan. The MICs of the isolates to test antibiotics were determined using the broth microdilution method. GeneXpert was used to detect genes encoding carbapenemases among the carbapenem-non-susceptible (NS) Enterobacterales isolates. RESULTS: The MIC values of the cefepime-enmetazobactam combination against extended-spectrum β-lactamase-producing E. coli and K. pneumoniae isolates (MIC90 ≤ 0.5 mg/L), blaKPC-harboring E. coli isolates (0.25 mg/L; n = 2), and 80% of blaOXA-48-like gene-harboring K. pneumoniae isolates (≤2 mg/L) were low. The MIC ranges of the cefepime-zidebactam against carbapenemase-producing Enterobacterales isolates (irrespective of the carbapenemase type [MIC90 ≤ 4 mg/L]) and carbapenem-NS or ceftolozane-tazobactam-NS P. aeruginosa isolates (MIC90 value, 8 mg/L) were significantly lower than those of the cefepime-enmetazobactam. CONCLUSIONS: The efficacy of novel antibiotics against important drug-resistant GNB must be monitored and validated during the clinical treatment of patients.
OBJECTIVES: To determine the in vitro activities of novel and comparator antibiotics against Gram-negative bacteria (GNB) in Taiwan. METHODS: Isolates of Escherichia coli (n = 335), Klebsiella pneumoniae (n = 316; 144 isolates with hyperviscosity characteristics), Pseudomonas aeruginosa (n = 271), Acinetobacter baumannii complex (n = 187), and non-typhoidal Salmonella species (n = 226), Shigella species (n = 13) from miscellaneous culture sources were collected in 2020 in Taiwan. The MICs of the isolates to test antibiotics were determined using the broth microdilution method. GeneXpert was used to detect genes encoding carbapenemases among the carbapenem-non-susceptible (NS) Enterobacterales isolates. RESULTS: The MIC values of the cefepime-enmetazobactam combination against extended-spectrum β-lactamase-producing E. coli and K. pneumoniae isolates (MIC90 ≤ 0.5 mg/L), blaKPC-harboring E. coli isolates (0.25 mg/L; n = 2), and 80% of blaOXA-48-like gene-harboring K. pneumoniae isolates (≤2 mg/L) were low. The MIC ranges of the cefepime-zidebactam against carbapenemase-producing Enterobacterales isolates (irrespective of the carbapenemase type [MIC90 ≤ 4 mg/L]) and carbapenem-NS or ceftolozane-tazobactam-NS P. aeruginosa isolates (MIC90 value, 8 mg/L) were significantly lower than those of the cefepime-enmetazobactam. CONCLUSIONS: The efficacy of novel antibiotics against important drug-resistant GNB must be monitored and validated during the clinical treatment of patients.
Authors: Liyan Cui; Ning Shen; Ping Yang; Chao Liu; Zhenchao Wu; Jiajia Zheng; Juan Yi; Nan Wu; Zhangli Wu; Ming Lu Journal: Infect Drug Resist Date: 2022-10-17 Impact factor: 4.177
Authors: Jose Cedano; Michelle Baez; Fernando Pasteran; Sabrina Daiana Montaña; Grace Ra; Venjaminne Fua; Alejandra Corso; Marcelo E Tolmasky; Robert A Bonomo; María Soledad Ramírez Journal: Front Cell Infect Microbiol Date: 2022-07-08 Impact factor: 6.073